Welcome to our new website. We have rebranded from Atnahs to Pharmanovia — read more

Since we first opened our doors in 2013, we have focused single-mindedly on delivering high-quality branded prescription medicines to patients, prescribers and healthcare providers across the globe. We specialise in the late-stage activities of development, co-development, licensing and acquisition.

Within our strategic therapeutic areas, we have developed our own innovative medicines as well as niche speciality products, and we have acquired tried and trusted medicines and iconic brands from innovator pharma companies and breathed new life into them.

From a single office in Basildon, we have grown consistently year on year. This has enabled us to reinvest in our products, our brands, our people, and to give back to our communities.

Our goal is to be an agile and imaginative global specialty pharma business and a preferred partner for innovator pharma companies.

Pharmacist looking at medicines in a cabinet

Our mission

  • Delivering medicines that patients, prescribers, healthcare providers and regulators value.
  • Investing evenly in acquisitive and organic growth, such that our business remains balanced from a portfolio and market perspective.
  • Maintaining a simple, lean operating model, working in depth with our partners.

This means that we need to be agile and imaginative, and it also means we need to be a preferred partner for innovator pharma companies.

Our strategy

We focus on late-stage activities to drive growth: developing, licensing and acquiring niche speciality products and established brands within our strategic therapeutic areas. We maintain a simple, lean operating model, working in-depth with our partners.

Chart icon

Business development

We develop, license and acquire niche speciality products and established brands.

We ensure these late-stage activities are all strategically complementary at the product and the therapeutic area level.

Cart icon

Commercial

We market and promote our products through our salesforces in Europe and globally.

We also engage third party salesforces for bespoke and targeted campaigns.

Chain icon

Supply chain

We partner with leading global manufacturers and logistics operators globally.

Our manufacturing network is primarily European and North American, but also covers India and China.

Document icon

Regulatory, quality & technical

We have in-house expertise to manage all aspects related to product regulatory, quality and technical.

We have significant experience in transfers of manufacturing (known as “technical transfers” or “TTs”), and have a strong track record of delivering in full and on time.

Our global presence

We focus on late-stage activities to drive growth: developing, licensing and acquiring niche speciality products and established brands within our strategic therapeutic areas. We maintain a simple, lean operating model, working in-depth with our partners.

  • Our markets
  • Planned operations
  • Our locations
Map with colours and pins denoting Pharmanovia's markets, locations and salesforces Map with colours, labels and pins denoting Pharmanovia's markets, locations and salesforces
Birds eye view of round-about in Basildon, UK

Basildon, UK (Headquarters)

Atnahs Pharma UK Ltd, Sovereign House, Miles Gray Road, Basildon, SS14 3FR, UK

Tower Bridge and The Shard, London, UK

London, UK

Atnahs Pharma UK Ltd, 13 David Mews, London, W1U 6EQ

Church in Breda, Netherlands

Breda, Netherlands

Lamepro BV, Burgemeester Guljélaan 2, 4837 CZ Breda, The Netherlands

Buildings in Copenhagen, Denmark

Copenhagen, Denmark

Pharmanovia A/S, Copenhagen Towers, Oerestads Boulevard 108, DK-2300 Copenhagen S, Denmark

Fountain in Zug, Switzerland

Zug, Switzerland

Atnahs Pharma Switzerland AG, Dammstrasse 19, 6300, Zug

Amphitheatre, Rome, Italy

Rome, Italy

Pharmanovia Italy Srl, Milano, Viale Abruzzi n. 94

The Sail building, Dubai, UAE

Dubai, UAE

Atnahs Pharma UK Ltd, Floor 01, Dubai Science Park (DSP) Laboratory Complex, Dubai, UAE

Singapore

Singapore

Pharmanovia APAC Pte Ltd, 1 Harbourfront Avenue, #13-03 Keppel Bay Tower, Singapore 098632

Sydney Opera House, Sydney, Australia

Sydney, Australia

Atnahs Pharma Australia Pty Ltd, C/o KPMG, Level 38, Tower 3, International Towers Sydney, 300 Barangaroo Avenue, Sydney, NSW 2000, Australia

Palace in Vadodara, India

Vadodara, India

Pharmanovia India Private Ltd, Nr. GIPCL Circle, New Sama Rd, New Sama, Vadodara, Gujarat 390024, India

Seoul, South Korea

Pharmanovia Korea Limited, FastFive SAMSEONG BRANCH 3, 12F – PO 1208, Teheran Ro 503, Gangnam Gu Seoul

Partnering with us

Find out more

Our history

2013

Dr. Amit Patel (our CEO) and his family found Atnahs and name us in honour of their grandmother, Shanta.

2014

We acquire Dipentum® from UCB, and expand into Western Europe, Australasia and Canada.

We open an agency office in Sydney, Australia to service our Australasian markets.

2015

We acquire Anaprox®, Naprosyn® and Toradol® from Roche, and expand into Eastern Europe, South East Asia and the US.

2016

We acquire Naproxen Suspension from Pediapharm.

We also acquire a majority stake in Pharmanovia, a specialty pharma business focused on co-development and licensing, and located in Copenhagen, Denmark.

2017

We acquire Bondronat®, Bonviva® and Kytril® from Roche, and expand into the Middle East, China, South Africa and Latin America.

Pharmanovia launches Dropizol® in Denmark. We open a branch office in Vadodara, India to act as our “Centre of Excellence” for Product Development.

2018

We acquire Famvir® from Novartis and expand into Russia. Pharmanovia launches Dropizol® in the rest of the Nordics and Germany.

We acquire the remainder of Pharmanovia.

2019

We acquire Synacthen® from Mallinckrodt.

We sell a majority stake to Triton to support us in our future growth strategy.

2020

We acquire Inderal®, Tenoretic®, Tenormin®, Zestoretic® and Zestril® from AstraZeneca, and expand into North Africa and Argentina.

We acquire Rocaltrol® from Roche.

We buy Takeda out of a Licence Agreement with Roche covering the sale of Bonviva® in 6 South East Asian markets.

We acquire Valium® from Roche.

2021

We change our corporate group name from Atnahs to Pharmanovia, the speciality pharma business that we acquired in 2016. This reflects our equal focus on development, co-development, licensing and acquisition.

We open offices in Zug (Switzerland), Rome (Italy) and Singapore.

2013

2014

2015

2016

2017

2018

2019

2020

2021